AIM Vaccine Co., Ltd. Class H (HK:6660) has released an update.
AIM Vaccine Co., Ltd. has received clinical trial approval for its second generation highly-effective absorbed tetanus vaccine from China’s National Medical Products Administration. This development is a significant step in the company’s strategy to expand its product line and strengthen its position in the growing multidisease vaccine market. The company is also advancing research on other vaccines, including a combined vaccine for diphtheria, tetanus, and acellular pertussis.
For further insights into HK:6660 stock, check out TipRanks’ Stock Analysis page.